New cell therapy a promising atherosclerosis treatment

Mar 01, 2011

Researchers at Karolinska Institutet have shown in a new study on mice, that cell therapy can be used to reverse the effect of 'bad' LDL cholesterol and reduce the inflammation that leads to atherosclerosis. The new cell therapy, which is presented in the prestigious scientific journal Circulation, can open the way for new therapies for stroke and myocardial infarction if the results prove translatable to humans.

Atherosclerosis is a chronic inflammation of the blood vessels. is transported in the blood in particles called LDL ('bad' cholesterol) that can accumulate in the vessel walls. This triggers the body's to react against LDL, which then cause inflammation in the vessels, and eventually thrombus formation. If such a thrombus forms in the , the patient suffers a ; if it forms in the , a can result.

The research group, under the direction of Professor Göran K Hansson at the Centre for Molecular Medicine, have developed a cell therapy that selectively dampens vascular inflammation induced by LDL. The therapy makes use of dendritic cells, which are characterized by a high degree of plasticity that renders them amenable to manipulation.

"With the appropriate treatment, dendritic cells can be made to inhibit rather than aggravate the inflammation around the LDL particles in the blood vessels," says Dr Andreas Hermansson, one of the researchers conducting the study. "A major advantage of this is that we can devise a treatment for vascular diseases that is highly specific."

The mouse studies now presented in Circulation have demonstrated substantial protective effects of the treatment, with a reduction of the atherosclerosis process of up around 70 percent. Last year, the researchers published results showing that antibodies recognizing the receptors that drive the immune reaction have protective effects, and now the same group is presenting a cell therapy that is at least as efficacious. It is hoped that this will pave the way for a completely new generation of selective anti-inflammatory therapies for cardiovascular disease.

"Treatments of atherosclerosis have traditionally targeted blood lipids, but a large proportion of treated patients still suffer life-threatening infarctions and stroke," says Professor Hansson. "We're now looking at the possibility of getting to the root of the problem and re-set, so to speak, the immune system's reaction to LDL, since it often has devastating consequences."

Explore further: Researcher discovers new method for creating bone tissue and cartilage tissue

More information: "Immunotherapy with tolerogenic apolipoprotein B-100 loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice", Andreas Hermansson, Daniel Johansson, Daniel F.J. Ketelhuth, John Andersson, Xinghua Zhou & Göran K. Hansson, Circulation, 28 February 2011; 123; 1083-1091. circ.ahajournals.org/

add to favorites email to friend print save as pdf

Related Stories

New atherosclerosis vaccine gives promising results

May 06, 2010

A new study by researchers at the Swedish medical university Karolinska Institutet shows that the immune defence's T cells can attack the "bad" LDL cholesterol and thereby cause an inflammation that leads to atherosclerosis. ...

Nicotinic acid blocks immune cells in atherosclerosis

Feb 07, 2011

Nearly all cardiac infarctions and around half of all strokes are caused by atherosclerosis. An early treatment of atherosclerosis is therefore crucial to preventing cardiovascular diseases. Stefan Offermanns’ ...

Inflammation worsens danger due to atherosclerosis

Jan 22, 2009

Current research suggests that inflammation increases the risk of plaque rupture in atherosclerosis. The related report by Ovchinnikova et al, "T cell activation leads to reduced collagen maturation in atherosclerotic plaques ...

Genes that protect against atherosclerosis identified

Mar 14, 2008

One way of combating atherosclerosis is to reduce levels of “bad cholesterol” in the blood. Scientists at the Swedish medical university Karolinska Institutet have now identified the genes that bring about this beneficial ...

Contribution of cholesterol transporter to vascular disease

Oct 26, 2007

Low-density lipoprotein (LDL), a transporter of cholesterol, may also contribute to vascular diseases by a previously unidentified mechanism, according to a report published online this week in EMBO reports. The study reveals ...

Recommended for you

Strategy proposed for preventing diseases of aging

19 hours ago

Medicine focuses almost entirely on fighting chronic diseases in a piecemeal fashion as symptoms develop. Instead, more efforts should be directed to promoting interventions that have the potential to prevent ...

User comments : 0